Table of Contents
Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing
Chapter 2 Executive Summary
2.1 Regenerative Medicine Market Outlook, 2014 – 2025
2.2 Regenerative Medicine Market : Segment Outlook, 2014 – 2025
2.3 Regenerative Medicine Market : Competitive Insights
Chapter 3 Regenerative Medicine Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2 Penetration & Growth Prospect Mapping for Therapeutic Category, 2018
3.3 Regenerative Medicine: Pipeline Analysis
3.3.1 Astellas Pharma Inc.
3.3.2 Bayer AG
3.3.3 AstraZeneca
3.3.4 F. Hoffmann-La Roche Ltd
3.3.5 Pfizer Inc.
3.3.6 Merck & Co., Inc.
3.3.7 Abbott (St. Jude Children’s Research Hospital)
3.3.8 Vericel Corporation
3.3.9 Novartis AG
3.3.10 GlaxoSmithKline plc.
3.3.11 Baxter
3.3.12 Boehringer Ingelheim GmbH
3.3.13 Amgen Inc.
3.3.14 Eli Lilly and Company
3.3.15 Bristol-Myers Squibb Company
3.3.16 TAKARA BIO INC.
3.3.17 Vital Therapies, Inc. (VTL)
3.3.18 Swedish Orphan Biovitrum
3.3.19 Stratatech Corporation
3.3.20 Stempeutics Research Pvt. Ltd
3.3.21 Soluble Systems, LLC
3.3.22 Smith & Nephew plc
3.3.23 Shire Pharmaceuticals Group PLC
3.3.24 Beike Biotechnology Co., Ltd.
3.3.25 SanBio, Inc.
3.3.26 ReNeuron Group plc
3.3.27 Regeneus Ltd.
3.3.28 Regen BioPharma, Inc
3.3.29 Q Therapeutics, Inc.
3.3.30 Promethera Biosciences
3.3.31 Pluristem Therapeutics, Inc. (PSTI)
3.3.32 Pharmicell Co., Ltd.
3.3.33 Osiris Therapeutics, Inc.
3.3.34 Orthofix International NV
3.3.35 Orthocell Limited
3.3.36 Takeda Pharmaceutical Company Limited
3.3.37 Caladrius
3.3.38 U.S. Stem cell Inc.
3.3.39 Cesca Therapeutics
3.3.40 Osiris Therapeutics Inc.
3.3.41 Astellas
3.3.42 Opex Therapeutics, Inc.
3.3.43 Northern Therapeutics, Inc.
3.3.44 Northern Therapeutics, Inc.
3.3.45 Neuralstem Inc.
3.3.46 Multigene Vascular Systems, Inc.
3.3.47 MEDIPOST Co.Ltd.
3.3.48 Mesoblast Ltd.
3.3.49 MacroCure, Inc.
3.3.50 Living Cell Technologies, Ltd.
3.4 Cost Structure Analysis
3.5 User Perspective Analysis
3.5.1. Consumer behavior analysis
3.5.2. Market influencer analysis
3.6 Technology Overview
3.7 Regulatory Framework
3.7.1 Regulatory environment: U.S.
3.7.2 Regulatory environment: Canada
3.7.3 Regulatory environment: Europe
3.7.4 Regulatory environment: Japan
3.7.4.1 Regenerative Medicine: Risk classification technique
3.7.5 Regulatory environment: China
3.7.6 Reimbursement framework
3.8 Regenerative Medicine Market – Market Dynamics
3.8.1 Market driver analysis
3.8.1.1 Presence of strong pipeline portfolio and high number of clinical trials
3.8.1.1.1 Major milestones & key events in regenerative medicine
3.8.1.2 High economic impact of regenerative medicine
3.8.1.3 Emerging applications of gene therapy in regenerative medicine
3.8.1.4 Government & private funding to support the development of regenerative medicine (High investment & funding to support development of RM)
3.8.1.5 Technological advances in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
3.8.1.6 Presence of strategic partnerships to accelerate development & commercialization of regenerative medicine
3.8.1.7 Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
3.8.2 Market restraint analysis
3.8.2.1 High cost of treatment
3.8.2.2 Regulatory issues pertaining stem cell, tissues engineering and regenerative medicine
3.8.3 Market challenges analysis
3.8.3.3 Ethical issues related to use of stem cell & regenerative medicines for R&D
3.9 Regenerative Medicine Market Analysis Tools
3.9.1 Industry Analysis – Porter’s
3.9.1.1 Supplier power : High supplier bargaining power owing rising number of cord blood banks
3.9.1.2 Buyer power: Moderate buyer bargaing power due to presence of strong pipeline of products
3.9.1.3 Substitution threat: Presence of synthetic scaffolds and stents results in moderate substitution threat
3.9.1.4 New entrants threat: Moderate threat of new entrants due to requirement of high capital
3.9.1.5 Competitive rivalry: High competitive rivalry due to adoption of various strategies by the key players
3.9.2 PESTEL analysis
3.9.2.1 Political landscape
3.9.2.2 Environmental landscape
3.9.2.3 Social landscape
3.9.2.4 Technology landscape
3.9.2.5 Legal landscape
3.9.3 Major deals & strategic alliances analysis
3.9.3.1 Joint ventures
3.9.3.2 Mergers & acquisitions
3.9.3.3 Licensing & partnership
3.9.3.4 Technology collaborations
3.9.3.5 Strategic divestments
3.9.4 Market entry strategies
3.9.5 Case studies
Chapter 4 Regenerative Medicine Market: Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis/ position analysis, 2018
4.4 Public Companies
4.4.1 Company market position analysis
4.4.2 Company market share/ranking by region
4.4.3 Competitive dashboard analysis
4.4.4 Market differentiators
4.4.5 Synergy analysis: Major deals & strategic alliances
4.5 Private Companies
4.5.1 List of key emerging companies
4.5.2 Funding outlook
4.5.3 Regional network map
4.5.4 Company market position analysis
4.5.5 List of supplier
Chapter 5 Regenerative Medicine Market Categorization: Product Type Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Product Type Market Share Analysis, 2018 & 2025
5.3 Regenerative Medicine Market: Product Type Movement Analysis, 2018 & 2025
5.4. Global Regenerative Medicine Market, by Product Type, 2014 to 2025
5.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
5.6 Therapeutics
5.6.1 Global regenerative medicine therapeutics market, 2014 – 2025 (USD Million)
5.6.2 Primary cell-based therapeutics
5.6.2.1 Global primary cell-bases therapeutics market, 2014 – 2025 (USD Million)
5.6.2.2 Dermatology
5.6.2.2.1 Various approaches for skin regeneration
5.6.2.2.2 Global dermatology primary cell-bases therapeutics market, 2014 – 2025 (USD Million)
5.6.2.3 Musculoskeletal
5.6.2.3.1 Global musculoskeletal primary cell-bases therapeutics market, 2014 – 2025 (USD Million)
5.6.2.4 Surgical
5.6.2.4.1 Global surgical primary cell-bases therapeutics market, 2014 – 2025 (USD Million)
5.6.2.5 Dental
5.6.2.5.1 Global dental primary cell-bases therapeutics market, 2014 – 2025 (USD Million)
5.6.2.6 Others
5.6.2.6.1 Global other primary cell-bases therapeutics market, 2014 – 2025 (USD Million)
5.6.3 Stem cell & progenitor cell-based therapeutics
5.6.3.1 Global stem cell & progenitor cell-based therapeutics market, 2014 – 2025 (USD Million)
5.6.3.2 Autologous
5.6.3.2.1 Global autologous stem cell & progenitor cell-based therapeutics market, 2014 – 2025 (USD Million)
5.6.3.3 Allogeneic
5.6.3.3.1 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2014 – 2025 (USD Million)
5.6.3.4 Others
5.6.3.4.1 Global other stem cell & progenitor cell-based therapeutics market, 2014 – 2025 (USD Million)
5.6.4 Cell-based Immunotherapies
5.6.4.1 Global cell-based immunotherapies market, 2014 – 2025 (USD Million)
5.6.5 Gene Therapies
5.6.5.1 Global gene therapies market, 2014 – 2025 (USD Million)
5.7 Tools
5.7.1 Global regenerative medicines tools market, 2014 – 2025 (USD Million)
5.7.2 Laboratory equipment
5.7.2.1 Global regenerative medicines laboratory equipment market, 2014 – 2025 (USD Million)
5.7.3 Reagents & other consumables
5.7.3.1 Global regenerative medicines reagents & other consumbales market, 2014 – 2025 (USD Million)
5.8 Banks
5.8.1 Global cell banks market, 2014 – 2025 (USD Million)
5.9 Services
5.9.1 Global regenerative medicine services market, 2014 – 2025 (USD Million)
5.10 Regenerative Medicine Product Type Market, byTherapeutic Category, 2014 to 2025
Chapter 6 Regenerative Medicine Market Categorization: Therapeutic Category Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Therapeutic Category Market Share Analysis, 2018 & 2025
6.3 Regenerative Medicine Market: Therapeutic Category Movement Analysis, 2018 & 2025
6.4. Global Regenerative Medicine Market, by Therapeutic Category, 2014 to 2025
6.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
6.6 Dermatology
6.6.1 Global dermatological therapeutics market, 2014 – 2025 (USD Million)
6.7 Musculoskeletal
6.7.1 Global musculoskeletal therapeutics market, 2014 – 2025 (USD Million)
6.8 Immunology & Inflammation
6.8.1 Global immunology & inflammation therapeutics market, 2014 – 2025 (USD Million)
6.9 Oncology
6.9.1 Global oncology therapeutics market, 2014 – 2025 (USD Million)
6.10 Cardiovascular
6.10.1 Global cardiovascular therapeutics market, 2014 – 2025 (USD Million)
6.11 Ophthalmology
6.11.1 Global ophthalmology therapeutics market, 2014 – 2025 (USD Million)
6.12 Others
6.12.1 Global other therapeutics market, 2014 – 2025 (USD Million)
Chapter 7 Regenerative Medicine Market Categorization: Regional Estimates & Trend Analysis, by Product And Therapeutic Category
7.1 Regenerative Medicine Market Share by Region, 2018 & 2025
7.2 Regional Market Share and Leading Players, 2018
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa
7.3 North America
7.3.1 North America regenerative medicines market, 2014 – 2025 (USD Million)
7.3.2 U.S.
7.3.2.1 U.S. regenerative medicine market, by product type, 2014 – 2025 (USD Million)
7.3.2.2 U.S. regenerative medicine market, by therapeutic category, 2014 – 2025 (USD Million)
7.3.3 Canada
7.3.3.1 Canada regenerative medicines market, by product type 2014 – 2025 (USD Million)
7.3.2.2 Canada regenerative medicine market, by therapeutic category, 2014 – 2025 (USD Million)
7.4 Europe
7.4.1 Europe regenerative medicines market, 2014 – 2025 (USD Million)
7.4.2 Germany
7.4.2.1 Germany regenerative medicines market, by product type 2014 – 2025 (USD Million)
7.4.2.2 Germany regenerative medicines market, by therapeutic category 2014 – 2025 (USD Million)
7.4.3 UK
7.4.3.1 U.K. regenerative medicines market, 2014 – 2025 (USD Million)
7.4.2.2 U.K. regenerative medicines market, by therapeutic category 2014 – 2025 (USD Million)
7.5 Asia Pacific
7.5.1 Asia Pacific regenerative medicines market, 2014 – 2025 (USD Million)
7.5.2 Japan
7.5.2.1 Japan regenerative medicines market, by product type 2014 – 2025 (USD Million)
7.5.2.2 Japan regenerative medicines market, by therapeutic category 2014 – 2025 (USD Million)
7.5.3 China
7.5.3.1 China regenerative medicines market, by product type 2014 – 2025 (USD Million)
7.5.2.2 China regenerative medicines market, by therapeutic category 2014 – 2025 (USD Million)
7.6 Latin America
7.6.1 Latin America regenerative medicines market, 2014 – 2025 (USD Million)
7.6.2 Brazil
7.6.2.1 Brazil regenerative medicines market, by product type 2014 – 2025 (USD Million)
7.6.2.2 Brazil regenerative medicines market, by therapeutic category 2014 – 2025 (USD Million)
7.7 Middle East & Africa (MEA)
7.7.1 Middle East & Africa regenerative medicines market, 2014 – 2025 (USD Million)
7.7.2 South Africa
7.7.2.1 South Africa regenerative medicines market, by product type 2014 – 2025 (USD Million)
7.7.2.2 South Africa regenerative medicines market, by therapeutic category 2014 – 2025 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
8.3.1 Integra LifeSciences Corporation
8.3.1.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.2 Astellas Pharma Inc.
8.3.2.1 Company overview
8.3.2.1.1 Ocata Therapeutics, Inc.
8.3.2.2 Financial performance
8.3.2.2.1 Financial Performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.3 Corline Biomedical AB
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 COOK BIOTECH, INC.
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.5 Bayer BV
8.3.5.1 Company overview
8.3.5.1.1 BlueRock Therapeutics
8.3.5.2 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 AstraZeneca
8.3.6.1 Company overview
8.3.6.1.1 MedImmune
8.3.6.2 Financial performance
8.3.6.3 Product benchmarking
8.3.6.4 Strategic initiatives
8.3.7 F. Hoffmann-La Roche Ltd
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 Pfizer Inc.
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.9 Merck & Co., Inc.
8.3.9.1 Company overview
8.3.9.1.1 Sigma-Aldrich Co. LLC
8.3.9.1.2 Merck Millipore
8.3.9.2 Financial performance
8.3.9.2.1 Financial performance
8.3.9.3 Product benchmarking
8.3.9.4 Strategic initiatives
8.3.10 Abbott
8.3.10.1 Company overview
8.3.10.1.1 St. Jude Medical, Inc.
8.3.10.2 Financial performance
8.3.10.2.1 Financial performance
8.3.10.3 Product benchmarking
8.3.11 Vericel Corporation
8.3.11.1 Company overview
8.3.11.2 Financial performance
8.3.11.3 Product benchmarking
8.3.11.4 Strategic initiatives
8.3.12 Novartis AG
8.3.12.1 Company overview
8.3.12.1.1 Alcon
8.3.12.2 Financial performance
8.3.12.3 Product benchmarking
8.3.12.4 Strategic initiatives
8.3.13 GlaxoSmithKline plc.
8.3.13.1 Company overview
8.3.13.2 Financial performance
8.3.13.3 Product benchmarking
8.3.13.4 Strategic initiatives
8.3.14 Baxter.
8.3.14.1 Company overview
8.3.14.1.1 Synovis Micro Companies Alliance Inc
8.3.14.2 Financial performance
8.3.14.3 Product benchmarking
8.3.15 Boehringer Ingelheim GmbH(C.H.Boehringer Sohn AG & Co.KG, Ingelheim)
8.3.15.1 Company overview
8.3.15.2 Financial performance
8.3.15.3 Product benchmarking
8.3.15.4 Strategic initiatives
8.3.16 Amgen Inc.
8.3.16.1 Company overview
8.3.16.2 Financial performance
8.3.16.3 Product benchmarking
8.3.16.4 Strategic initiatives
8.3.17 Eli Lilly and Company
8.3.17.1 Company overview
8.3.17.2 Financial performance
8.3.17.3 Product benchmarking
8.3.17.4 Strategic initiatives
8.3.18 Bristol-Myers Squibb Company
8.3.18.1 Company overview
8.3.18.1.1 iPierian, Inc
8.3.18.2 Financial performance
8.3.18.3 Product benchmarking
8.3.18.4 Strategic initiatives
8.3.19 Nuvasive, Inc.
8.3.19.1 Company overview
8.3.19.2 Financial performance
8.3.19.3 Product benchmarking
8.3.19.4 Strategic initiatives
8.3.20 Organogenesis, Inc.
8.3.20.1 Company overview
8.3.20.1.1 NuTech
8.3.20.2 Financial performance
8.3.20.2.1 Financial performance
8.3.20.3 Product benchmarking
8.3.20.4 Strategic initiatives
8.3.21 MiMedx Group, Inc.
8.3.21.1 Company overview
8.3.21.1.1 Stability, LLC.
8.3.21.2 Financial performance
8.3.21.3 Product benchmarking
8.3.21.4 Strategic initiatives
8.3.22 TAKARA BIO INC.
8.3.22.1 Company overview
8.3.22.2 Financial performance
8.3.22.3 Product benchmarking
8.3.22.4 Strategic initiatives
8.3.23 Caladrius Biosciences, Inc.
8.3.23.1 Company overview
8.3.23.2 Financial performance
8.3.23.3 Product benchmarking
8.3.23.4 Strategic initiatives
8.3.24 U.S. Stem Cell, Inc.
8.3.24.1 Company overview
8.3.24.2 Financial performance
8.3.24.3 Product benchmarking
8.3.24.4 Strategic initiatives
8.3.25 Cesca Therapeutics
8.3.25.1 Company overview
8.3.25.2 Financial performance
8.3.25.3 Product benchmarking
8.3.25.4 Strategic initiatives
8.3.26 Osiris Therapeutics, Inc
8.3.26.1 Company overview
8.3.26.2 Financial performance
8.3.26.3 Product benchmarking
8.3.26.4 Strategic initiatives
8.4 List of Companies
TABLE 1 U.S.: Estimated costs involved in disease area and their associated cell- and gene-based therapies
TABLE 2 Global landscape: Number of regenerative medicine companies including cell therapeutic companies
TABLE 3 2016: Clinical trials in industry by technology type
TABLE 4 Tax incentives for life science R&D in leading countries
TABLE 5 Deaths attributable to neurological disorders as percentage of total deaths
TABLE 6 Estimated prevalence and number of people with diabetes (adult 18+ years)
TABLE 7 Global cancer incidences, 2017
TABLE 8 Summary of cystic fibrosis foundation patient registry (2014 & 2015)
TABLE 9 Regulatory status of cell-based tissue engineering & regenerative medicine
TABLE 10 FDA stratification of somatic cell therapy products based on intended use and extent of manipulation
TABLE 11 Collaborative networks and infrastructures that support regenerative medicine in Canada
TABLE 12 State Food and Drug Administration (SFDA) approved stem cell products
TABLE 13 Stem cell research institutes in China
TABLE 14 SFDA approved tissue-engineering products
TABLE 15 Regenerative medicine used in patients
TABLE 16 Various approaches in regenerative medicine for dermatological use
TABLE 17 Various types of scaffolds in in vitro study
TABLE 18 Predicted prevalence of Osteoporosis and Low Bone Mass for 2010 & 2030
TABLE 19 Prevalence of ophthalmic diseases in U.S
TABLE 20 Global burden of neurological diseases: Projected number of Disability Adjusted Life Years (DALYs) for neurological disorders
TABLE 21 North America: Clinical studies using HCT for hematopoietic and non-hematopoietic conditions (2016)
TABLE 22 North America regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 23 North America regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 24 North America primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 25 North America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 26 North America regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 27 North America regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 28 U.S. regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 29 U.S. regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 30 U.S. primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 31 U.S. stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 32 U.S. regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 33 U.S. regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 34 Projected economic output of Canada's stem cell industry between 2015 and 2025
TABLE 35 Canada regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 36 Canada regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 37 Canada primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 38 Canada stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 39 Canada regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 40 Canada regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 41 Europe regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 42 Europe regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 43 Europe primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 44 Europe stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 45 Europe regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 46 Europe regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 47 Germany regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 48 Germany regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 49 Germany primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 50 Germany stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 51 Germany regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 52 Germany regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 53 U.K.: National action in regenerative medicine
TABLE 54 U.K.: Funds for regenerative medicine research: 2012-2017 (in USD million)
TABLE 55 U.K. regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 56 U.K. regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 57 U.K. primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 58 U.K. stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 59 U.K. regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 60 U.K. regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 61 Asia Pacific regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 62 Asia Pacific regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 63 Asia Pacific primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 64 Asia Pacific stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 65 Asia Pacific regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 66 Asia Pacific regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 67 Japan regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 68 Japan regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 69 Japan primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 70 Japan stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 71 Japan regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 72 Japan regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 73 Main monographs published in china
TABLE 74 China regenerative medicines market estimates& forecasts, by product, 2014 -2025 (USD Million)
TABLE 75 China regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 76 China primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 77 China stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 78 China regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 79 China regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 80 Latin America: Current initiatives and opportunities
TABLE 81 Latin America regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 82 Latin America regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 83 Latin America primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 84 Latin America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 85 Latin America regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 86 Latin America regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 87 Brazil regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 88 Brazil regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 89 Brazil primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 90 Brazil stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 91 Brazil regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 92 Brazil regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 93 Middle East & Africa regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 94 Middle East & Africa regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 95 Middle East & Africa primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 96 Middle East & Africa stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 97 Middle East & Africa regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 98 Middle East & Africa regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
TABLE 99 South Africa regenerative medicines market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 100 South Africa regenerative therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 101 South Africa primary cell-bases therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 102 South Africa stem cell & progenitor cell-based therapeutics market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 103 South Africa regeneratve medidince tools market estimates& forecasts, by product, 2014 - 2025 (USD Million)
TABLE 104 South Africa regenerative medicine market estimates& forecasts, by therapeutic category, 2014 - 2025 (USD Million)
【レポートのキーワード】
再生医療、治療学、ツール、銀行、サービス、皮膚科、筋骨格、免疫および炎症、腫瘍学、心血管、眼科
【免責事項】
https://www.marketreport.jp/reports-disclaimer
